Digest Réseau Comment ça marche
Réseau
/
Sociétés
Pr
Non vérifié

ProMIS Neurosciences Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologiePhotographiePublicité/Marketing/Médias/Communication

9 communiqués de presse

Voir tous les communiqués de presse
18/12/2025
Biotechnologie
Annonces Économiques
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Source
ProMIS Neurosciences Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
10/12/2025
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Source
ProMIS Neurosciences Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
01/12/2025
Biotechnologie
Photographie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Source
ProMIS Neurosciences Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
01/12/2025
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Source
ProMIS Neurosciences Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
22/10/2025
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
Source
ProMIS Neurosciences Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
03/09/2025
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Source
ProMIS Neurosciences Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
13/08/2025
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
Source
ProMIS Neurosciences Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
29/07/2025
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
Source
ProMIS Neurosciences Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
21/07/2025
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
Source
ProMIS Neurosciences Inc.
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0